{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:37:58Z","timestamp":1793835478843,"version":"4.6.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Graves' Orbitopathy (GO) is an autoimmune disorder characterized by inflammation of orbital tissues, leading to various ocular manifestations, including ocular surface disease. This cross-sectional study aimed to assess the presence of ocular surface disease using the Ocular Surface Disease Index (OSDI) in patients with Graves' disease (GD) and moderate-to-severe active GO compared to those with GD and mild non-active GO. Additionally, we aimed to investigate the correlation between ocular surface disease and the eye features of GO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive GD patients with GO referred to the Ophthalmology and Endocrinology Units of the University Hospital of Pisa between June 2022 and February 2023 were enrolled. OSDI scores were obtained from 79 GD patients, categorized into moderate-to-severe active GO and mild non-active GO groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>OSDI scores were significantly higher in patients with moderate-to-severe active GO compared to those with mild non-active GO (P=0.0006). A cutoff value of 33 for positive tests revealed a higher frequency of pathological OSDI in moderate-to-severe active GO patients compared to mild non-active GO patients (P=0.0221; OR 3.673, CI 1.277-9.531). Within the moderate-to-severe active GO group, a significant positive correlation was found between OSDI and Clinical Activity Score (CAS) (R= 0.3867, 95% CI from 0.1403 to 0.5880; P=0.0030). Using a cutoff value of 55 (the 75th percentile of the study population), patients with CAS \u2265 3 had a significantly higher proportion of pathological OSDI compared to those with CAS &amp;lt;3 (P=0.0039; OR 4.075, CI 1.619-10.39). Proptosis values \u2265 22 mm and the presence of lagophthalmos were identified as significant risk factors for ocular surface disease development (P=0.0406 and P=0.0493, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our study highlights a significantly higher prevalence of ocular surface disease, as measured by OSDI, in patients with moderate-to-severe active GO compared to those with mild non-active disease. The degree of GO activity positively correlates with ocular surface involvement, and proptosis and lagophthalmos increase the risk of its occurrence. These findings emphasise the importance of assessing and managing ocular surface health in GO patients. Early identification and appropriate treatment of ocular surface disease need to be pursued to improve patient management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1428185","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:21:04Z","timestamp":1733372464000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Ocular surface disease index in Graves\u2019 orbitopathy: a cross-sectional study"],"prefix":"10.3389","volume":"15","author":[{"given":"Maria Novella","family":"Maglionico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lanzolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Figus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Posarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 european thyroid association\/european group on graves\u2019 Orbitopathy guidelines for the management of graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0475","article-title":"Role of the underlying thyroid disease on the phenotype of graves\u2019 Orbitopathy in a tertiary referral center","volume":"25","author":"Leo","year":"2015","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1555762","article-title":"Current insights into the pathogenesis of graves\u2019 Ophthalmopathy","volume":"47","author":"Bahn","year":"2015","journal-title":"Horm Metab Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S76583","article-title":"The relationship between Graves\u2019 ophthalmopathy and dry eye syndrome","volume":"9","author":"Selter","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtos.2022.02.001","article-title":"Ocular surface disease in thyroid eye disease: A narrative review","volume":"24","author":"Rana","year":"2022","journal-title":"Ocul Surf"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3109\/02713683.2010.526285","article-title":"Ocular surface and dry eye in graves\u2019 Disease","volume":"36","author":"G\u00fcrdal","year":"2011","journal-title":"Curr Eye Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/01676830.2013.764440","article-title":"Ocular surface changes in thyroid eye disease","volume":"32","author":"Ismailova","year":"2013","journal-title":"Orbit"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.12.007","article-title":"Occult thyroid eye disease in patients presenting with dry eye symptoms","volume":"147","author":"Gupta","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"key":"B11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/00055735-200408000-00004","article-title":"Dry eye diagnosis and management in 2004","volume":"15","author":"Perry","year":"2004","journal-title":"Curr Opin Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1167\/iovs.10-6997e","article-title":"The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on the Epidemiology of, and Associated Risk Factors for, MGD","volume":"52","author":"Schaumberg","year":"2011","journal-title":"Investig Opthalmol Vis Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.005","article-title":"TFOS DEWS II introduction","volume":"15","author":"Nelson","year":"2017","journal-title":"Ocul Surf"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.1983.tb01401.x","article-title":"OCULAR SURFACE DRYING AND TEAR FILM OSMOLARITY IN THYROID EYE DISEASE","volume":"61","author":"Gilbard","year":"2009","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32836227bf","article-title":"Hormones and dry eye syndrome: an update on what we do and don\u2019t know","volume":"24","author":"Rocha","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0889-8529(18)30485-7","article-title":"Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy","volume":"16","author":"Bahn","year":"1987","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2018.07.003","article-title":"Subjective versus objective dry eye disease in patients with moderate-severe thyroid eye disease","volume":"16","author":"Kashkouli","year":"2018","journal-title":"Ocul Surf"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S317708","article-title":"Ocular surface changes in patients with thyroid eye disease: an observational clinical study","volume":"15","author":"Allam","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-4432.2012.02.003","article-title":"Ocular surface characteristics and impression cytology in patients with active versus inactive Thyroid Eye Disease","volume":"27","author":"Xu","year":"2012","journal-title":"Eye Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093066","article-title":"Ocular surface changes in treatment-naive thyroid eye disease","volume":"12","author":"Liao","year":"2023","journal-title":"J Clin Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1428185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:21:10Z","timestamp":1733372470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1428185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":21,"alternative-id":["10.3389\/fendo.2024.1428185"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1428185","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"article-number":"1428185"}}